Clinical trials: Myocardial Revascularization
Coronary Artery Disease, Drug Eluting Balloon
Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two…
- Conditions
- Coronary Artery Disease, Drug Eluting Balloon, Drug Eluting Stent
- Trial name
- SPARX RCT (NCT07397845)
- Testing
- Protégé and Protégé NC, Agent, Drug Eluting Stent
- Where
- Switzerland
- Volunteers
- 1,380 people
- Sponsor
- Translumina GmbH
Coronary Artery Disease
A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease
The primary objective of this study is to assess the safety and effectiveness of same sitting, simultaneous hybrid robotic assisted coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in the…
- Trial name
- NCT00928356
- Testing
- Hybrid CABG/PCI, Off Pump CABG
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Pinnacle Health Cardiovascular Institute
Acute Myocardial Infarction, Cardiogenic Shock
Extracorporeal Life Support in Cardiogenic Shock
The aim of the study is to examine whether treatment with extracorporeal life support (ECLS) in addition to revascularization with percutaneous coronary intervention (PCI) or alternatively coronary artery bypass grafting (CABG)…
- Trial name
- ECLS-SHOCK (NCT03637205)
- Testing
- ECLS insertion, Revascularisation and optimal medical treatment
- Where
- 46 sites in Germany, Slovenia
- Volunteers
- 420 people
- Sponsor
- Helios Health Institute GmbH
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Multivessel Coronary Artery Disease, STEMI
The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI
In patients with ST elevation myocardial infarction (STEMI) the treatment goal is revascularization of the occluded artery with the use of primary percutaneous coronary intervention (PCI).
- Conditions
- Multivessel Coronary Artery Disease, STEMI, FFR Guided PCI
- Trial name
- FAIO (NCT02637440)
- Testing
- FFR guided PCI, Angio guided PCI
- Where
- 2 sites in Ireland
- Volunteers
- 560 people
- Sponsor
- University of Limerick
Coronary Artery Disease, Myocardial Ischemia
Genoss DES Prospective Multicenter Registry
This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT03045913
- Testing
- Genoss DES
- Where
- 17 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Young Jin Youn, MD, PhD
Coronary Disease
Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD
This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with…
- Trial name
- ASSIST (NCT05529459)
- Testing
- Percutaneous Coronary Intervention
- Where
- 17 sites in South Korea
- Volunteers
- 2,400 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Romania Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01593059
- Where
- 4 sites in Romania
- Volunteers
- 13 people
- Sponsor
- Biotronik Vertriebs-GmbH
Angina Pectoris, Unstable Angina
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.
- Conditions
- Angina Pectoris, Unstable Angina, Myocardial Infarction
- Trial name
- NCT00317512
- Testing
- Percutaneous Coronary Revascularization, Hemoglobin-Based Oxygen Carrier-201 (HBOC-201), Voluven
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 45 people
- Sponsor
- Biopure Corporation
Acute Myocardial Infarction, Revascularization
Long Term Predictors of Acute Myocardial Infarction in Patients With Coronary Revascularization
Worldwide, Ischemic heart disease is the single most common fatal disease. One of the most common causes of acute myocardial infarction is represented by obesity.
- Trial name
- NCT06546228
- Testing
- No intervention. Only observational.
- Where
- Italy
- Volunteers
- 652 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Coronary Artery Disease, Myocardial Ischemia
Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
To assess the feasibility of coronary computed tomography angiography (CTA) and fractional flow reserve derived from CTA (FFRCT) to replace invasive coronary angiography (ICA) as a surgical guidance method for planning and…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases
- Trial name
- NCT04142021
- Testing
- Coronary computed tomography angiography
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 114 people
- Sponsor
- National University of Ireland, Galway, Ireland
STEMI
CMR or Angiography for FFR-guided Revascularisation
Around 50% of patients that present with ST Elevation Myocardial Infarction (STEMI) have residual disease in the non-culprit lesions.
- Trial name
- CRAFT-MI (NCT03408912)
- Testing
- FFR
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
Validation of vFFR as Compared to FFR to Guide Revascularization of Non-culprit Lesions in STEMI Patients
This prospective multicenter observational cohort study is designed to study the diagnostic performance of acute-setting angiography-based FFR (e.g.
- Conditions
- ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- NCT05698719
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 111 people
- Sponsor
- Erasmus Medical Center
Coronary Heart Disease (CHD)
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy
This study is dedicated to determination of the long term effectiveness of coronary heart disease (CHD) treatments - cardiac shock wave therapy (CSWT) in comparison with other kinds of medical and surgical treatment.
- Trial name
- CSWTSPB40 (NCT01631409)
- Testing
- Treatment of CHD risk factors, Aspirin, Isosorbide mononitrate, Atenolol, Enalapril., PCA
- Sponsor
- City Hospital No 40, Saint Petersburg, Russia
Myocardial Infarction, Ischemia
FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.
Few reports described outcomes of complete compared with infarct related artery (IRA) only revascularization in patients with ST elevation myocardial infarction (STEMI) and multivessel coronary disease (CAD).
- Conditions
- Myocardial Infarction, Ischemia, Heart Failure, Necrosis
- Trial name
- FIT (NCT01160900)
- Testing
- Coronary angioplasty all lesions
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Coronary Artery Disease
Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization
The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial. A total of 2228 participants will be randomized in a 1:1 fashion to either vFFR- or FFR guided revascularization.
- Trial name
- FAST III (NCT04931771)
- Testing
- vFFR guided revascularization, FFR guided revascularization
- Where
- 40 sites in France, Germany and 5 more
- Volunteers
- 2,235 people
- Sponsor
- ECRI bv
Coronary Disease, Coronary Heart Disease
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping…
- Conditions
- Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis
- Trial name
- NCT00117936
- Testing
- Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- Volunteers
- 150 people
- Sponsor
- Venturis Therapeutics, Inc.